@article{7de99ac095514c3180b1bd58825d98f1,
title = "A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption",
abstract = "Background: Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking. Objective: We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash. Methods: In all, 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face. At baseline, week 2, and week 5, a dermatologist performed facial lesion counts, patients reported perceived severity of rash-related symptoms, and standardized facial photographs were obtained for blinded evaluation of global rash severity. Results: Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 (P < .001) and 5 (P = .02). However, there were no significant differences in patients' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides. Limitations: This study was not placebo controlled. Conclusions: Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash.",
keywords = "acnelike rash, cetuximab, clinical trial, pimecrolimus",
author = "Alon Scope and Lieb, {Jocelyn A.} and Dusza, {Stephen W.} and Phelan, {Deborah L.} and Myskowski, {Patricia L.} and Leonard Saltz and Halpern, {Allan C.}",
note = "Funding Information: Supported by an investigator-initiated grant from Bristol-Myers Squibb and ImClone Systems Inc. Funding Information: Disclosure: Dr Saltz is a compensated consultant for ImClone, Genentech, Roche, Alchemia, YM Bioscience, Merck, Pfizer, and Bristol-Myers Squibb, and has funded research from Bristol-Myers Squibb, ImClone, Genentech, Roche, Pfizer, Merck, and Taiho. Dr Halpern received honoraria and research funding from Bristol-Myers Squibb. Mr Dusza owns stock of Bristol-Myers Squibb. Drs Scope, Lieb, and Myskowski and Ms Phelan have no conflicts of interest to declare. ",
year = "2009",
month = oct,
doi = "10.1016/j.jaad.2009.03.046",
language = "אנגלית",
volume = "61",
pages = "614--620",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Elsevier Inc.",
number = "4",
}